logo
Select company
Select metric
Ticker Information

Ticker

STRO

Company Name

SUTRO BIOPHARMA INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

SUTRO BIOPHARMA INC - Capital Expenditures to Operating Cash Flow Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

STRO - CapEx/OCF Historical data
DateCapital ExpenditureCapital Expenditures to Operating Cash FlowNet Cash Flow - Operations
6/30/2025$ 3.16M0%$ -248.86M
3/31/2025$ 3.83M0%$ -194.68M
12/31/2024$ 3.1M0%$ -191.54M
9/30/2024$ 3.47M0%$ -105.73M
6/30/2024$ 2.97M0%$ -74.72M
3/31/2024$ 3.82M0%$ -115.37M
12/31/2023$ 4.32M0%$ -111.62M
9/30/2023$ 6.24M0%$ -149.55M
6/30/2023$ 6.65M0%$ -50.2M
3/31/2023$ 7.25M0%$ -22.19M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • SUTRO BIOPHARMA INC's latest trailing twelve months (TTM) CapEx/OCF stands at 0%.
  • Over the past 5 years, SUTRO BIOPHARMA INC's average CapEx/OCF has been 170.95%.
  • The median CapEx/OCF for SUTRO BIOPHARMA INC during this period was 170.95%
  • SUTRO BIOPHARMA INC reached its highest CapEx/OCF over the past 5 years at 221.41%.
  • The lowest CapEx/OCF recorded by SUTRO BIOPHARMA INC in the same timeframe 120.49%

SUTRO BIOPHARMA INC's CapEx/OCF vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

CapEx/OCF Benchmarks
CompanyCapEx/OCF
IPSC : CENTURY THERAPEUTICS INC -IGMS : IGM BIOSCIENCES INC -FBIO : FORTRESS BIOTECH INC -DOMH : DOMINARI HOLDINGS INC -MGX : METAGENOMI INC -ASRT : ASSERTIO HOLDINGS INC -LUNG : PULMONX CORP -KPTI : KARYOPHARM THERAPEUTICS INC -ICCC : IMMUCELL CORP 29.2%ATRA : ATARA BIOTHERAPEUTICS INC -

Definition of Capital Expenditures to Operating Cash Flow

[Calculation] The CapEx to Operating Cash Flow ratio, measures how much of a company’s operating cash flow is reinvested into productive [Assets]. It is capital expenditures [CapEx] divided by net operating cash flow [NCFO].
CapEx / CF - Operations
(=) CapEx/OCF
CapEx/OCF for SUTRO BIOPHARMA INC is calculated as follows: CapEx [ $ 7.55M ] / CF - Operations [ $ -62.08M ]
(=) CapEx/OCF [ 0% ]

STRO - Capital Expenditures to Operating Cash Flow, Last 5 years

120.49%

Minimum

Sep 30, 2022

221.41%

Maximum

Dec 31, 2022

170.95%

Average

170.95%

Median

CapEx/OCF Benchmark Analysis

The chart above depicts the distribution of CapEx/OCF for companies in the Total Stock Market. The average CapEx/OCF of the companies is 31.82% with a standard deviation of 29.54%.
The following table provides additional summary stats:
CapEx/OCF in the Market:
filtered constituents2.35K
min0.01%
max128%
average31.82%
median22.41%
std29.54%